The clinical samples from a large cohort can help evaluate the reliability of NEAT1 as a biomarker for ovarian cancer, which might be also employed to predict the prognosis of patients receiving chemotherapy, targeted therapy, and immunotherapy. This evidence concerns the gene NEAT1 and ovarian carcinoma.